Recce Pharmaceuticals

Recce Pharmaceuticals ROE

The Return on Equity (ROE) of Recce Pharmaceuticals (RCE.AX) as of Oct 12, 2026 is 89.47 %. In the previous year, Return on Equity (ROE) was 702.10 % — a change of -87.26% (lower).

ROE

89.47 %

YoY

-87.26%

Last updated:

In 2026, Recce Pharmaceuticals's return on equity (ROE) was 89.47 %, a -87.26% increase from the 702.10 % ROE in the previous year.

The Recce Pharmaceuticals ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2019
687.67 AUD
Jan 1, 2020
-186.66 AUD
Jan 1, 2021
-65.91 AUD
Jan 1, 2022
-109.19 AUD
Jan 1, 2023
505.15 AUD
Jan 1, 2024
185.45 AUD
Jan 1, 2025
702.10 AUD
Jan 1, 2026
89.47 AUD
The Recce Pharmaceuticals ROE history
YEARROEYoY
89.47 %-87.26%
702.10 %+278.59%
185.45 %-63.29%
505.15 %-562.62%
-109.19 %+65.68%
-65.91 %-64.69%
-186.66 %-127.14%
687.67 %-385.42%
-240.93 %-53.00%
-512.67 %+272.17%
-137.75 %+1,342.51%
-9.55 %-101.97%
484.82 %—
Access this data via the Eulerpool API
Get Free API Key

Recce Pharmaceuticals Stock analysis

What does Recce Pharmaceuticals do? Recce Pharmaceuticals is one of the most popular companies on Eulerpool.

ROE Details

Decoding Recce Pharmaceuticals's Return on Equity (ROE)

Recce Pharmaceuticals's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Recce Pharmaceuticals's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Recce Pharmaceuticals's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Recce Pharmaceuticals’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Recce Pharmaceuticals stock

Return on Equity (ROE) of Recce Pharmaceuticals is 89.47 % in 2026.

Return on Equity (ROE) of Recce Pharmaceuticals changed from 702.10 % to 89.47 %, representing a -87.26% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Recce Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Recce Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API
Get Free API Key

Profitability — Recce Pharmaceuticals

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Recce Pharmaceuticals